HealthMore in Health→
FDA Approves Regeneron’s Otarmeni, Marking a First for Inherited Hearing Loss Gene Therapy
Key Takeaways
- Regeneron says Otarmeni is the first FDA-approved gene therapy for a rare inherited hearing loss.
- The approval was reported on April 23, 2026.
- The company says it plans to offer the therapy free in the U.S.
DE
DT Editorial Team··via endpoints.news